Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …

Background Combination long-acting bronchodilator treatment might be more effective than
long-acting bronchodilator monotherapy for the treatment of chronic obstructive pulmonary …

Study objective To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/β 2-agonist combination umeclidinium/vilanterol (UMEC/VI) …

Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity, mortality,
and health care expenditure worldwide. Relaxation of airway smooth muscle with inhaled …

Background Combination long-acting bronchodilator therapy may be more effective than
long-acting bronchodilator monotherapy in COPD. Our objectives were to compare the …

Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and
should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; …

Background The long-acting muscarinic antagonist (LAMA) umeclidinium (UMEC) and the
combination of UMEC with the long-acting β 2-agonist (LABA) vilanterol (UMEC/VI) are …

Efficacy and safety of umeclidinium administered in a dry power inhaler were evaluated in
moderate-to-very-severe chronic obstructive pulmonary disease patients. This was a …

Background Two once-daily long-acting muscarinic antagonists (LAMAs) are currently
available for the treatment of chronic obstructive pulmonary disease (COPD)–tiotropium and …

Combinations of drugs with distinct and complementary mechanisms of action may offer
improved efficacy in the treatment of chronic obstructive pulmonary disease (COPD). In two …